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ABSTRACT 
Background: Women account for over half of persons living with HIV/AIDS globally. We 
examined geographic variation in all-cause mortality after antiretroviral therapy (ART) for 
women living with HIV (WLWH) worldwide. 
Methods: We pooled data from WLWH ≥18 years initiating ART 2000-2014 within COHERE 
(Europe) and IeDEA regions (East Africa, West Africa, South Africa, North America, Latin 
America/Caribbean). Mortality rates were calculated at 0-3, 3-6, 6-12, 12-24 and 24-48 
months after ART, and mortality rate ratios were compared to European rates with piecewise 
exponential parametric survival models based on Poisson regression. 
Findings: 190,175 WLWH (16% Europe, 47% East Africa, 13% West Africa, 19% South 
Africa, 1% South America, 3% North America and 2% Central America/Caribbean) were 
included. The highest death rates occurred 0-3 months after ART [1·51 (95%CI: 1·25–1·82) 
per 100 person-years in Europe, 12·45 (11.30–13.73), 14.03 (13.12–15.02) and 9.44 (8.80–
10.11) in East, West and South Africa, and 1.53 (0.97–2.43), 7.83 (5.44–11.27) and 17.02 
(14.62–19.81) in North, South America and Central America/Caribbean, respectively] and 
declined thereafter. Mortality in Europe was the lowest, with regional differences greatest in 
the first 3 months and smaller at longer ART durations [adjusted rate ratios 24-48 months 
after ART: 3.63 (95%CI: 3.04–4.33), 5.61 (4.84–6.51) and 3.47 (2.97–4.06) for East, West 
and South Africa; 2.86 (2.26-3.62), 2.42 (1.65–3.55) and 2.50 (1.92–3.26) for North, South 
America and Central America/Caribbean, respectively].  
Conclusions: Global variations in short- and long-term mortality among WLWH initiating 
ART may inform context-specific interventions. 
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INTRODUCTION 
 
The HIV pandemic continues to be a global health challenge; 36.9 million persons were 
estimated to be living with HIV in 2017 (1). Women account for over half of the adults living 
with HIV worldwide and up to 60% of persons from low and middle-income settings, where 
health needs are the most pressing (1-2).  
 
Access to health care and life-saving antiretroviral therapy (ART) varies greatly across 
regions and depends on structural and individual factors (1-3). Access to HIV testing is a 
prerequisite to ART initiation, but delayed HIV diagnosis and linkage to care are major 
barriers to timely access to ART and thus its clinical benefits (3-6). Largely a consequence of 
increases in the uptake of universal HIV screening during pregnancy to prevent mother-to-
child HIV transmission over the last decade, women from most geographical regions are 
diagnosed with HIV earlier and have higher CD4 cell counts at diagnosis than heterosexually 
infected men (1, 3-6). These factors underlie some of the reported mortality differences 
between women and men favoring females (7-11). However, no study has so far specifically 
compared early and late mortality differences among women living with HIV (WLWH) across 
different geographical regions worldwide.  
 
Globally, WLWH differ in their age distribution, HIV transmission routes, socio-economic 
status and viral and tuberculosis co-infection rates, and risk factors for non-HIV mortality (1, 
3-11).  Wide variations exist between countries and regions of the world in terms of access to 
HIV testing, ART regimens, and CD4 cell counts at ART initiation, along with HIV testing 
policies and guidelines for treatment. Many of these factors may be due to health care 
systems and resource availability for healthcare within the individual country. In turn, this 
may impact mortality rates for WLWH (1, 2, 12). Finally, background mortality rates in 
different regions have striking variations that, together with the previously mentioned 
aspects, shape the mortality rates of WLWH (13). Collaboration between large multiregional 
cohorts from different regions of the world provides an opportunity to describe geographic 
disparities in mortality. In this work, we estimate all-cause mortality after ART initiation, 
overall and by duration of ART use, among WLWH in Europe, the Americas and Sub-
Saharan Africa up to 48 months after ART initiation, in order to help to understand key 
underlying drivers of mortality in women from different settings.  
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METHODS 
 
Setting and data sources 
We merged databases from HIV cohorts in the International epidemiology Databases to 
Evaluate AIDS (IeDEA) Collaboration and the Collaboration of Observational HIV 
Epidemiological Research in Europe (COHERE) in EuroCoord (merger 2015). These 
collaborations have been described elsewhere (14-19).        
 
IeDEA is an international research consortium that collects HIV/AIDS data through seven 
international regional centers, four in Africa and one each in the Asia-Pacific region; the 
Caribbean, Central and South America region; and North America. Five IeDEA regions 
contributed data to this study: the North American AIDS Cohort Collaboration on Research 
and Design (NA-ACCORD) (14), the Caribbean, Central and South America network for HIV 
epidemiology (CCASAnet) (15) and IeDEA East (16), Southern (16) and West Africa (16). 
COHERE is a collaboration of HIV cohorts across Europe comprising 40 cohorts and cohort 
collaborations from 34 countries (17). COHERE includes other collaborations such as 
CASCADE (18) and EuroSIDA (19). 
 
Institutional review boards approved the pooling of data and their use in collaborative 
analyses, and ethics permission was granted. 
 
Study population and inclusion criteria 
Eligible individuals were ART-naïve women, 18-80 years old at ART initiation, who started 
their first ART regimen between 1st January 2000 and 31st December 2014. North American 
participants were required to have a second visit within 12 months of enrollment, regardless 
of ART initiation status, so that anyone who died soon after enrollment would not have been 
included in NA-ACCORD. In Southern Africa analyses were restricted to cohorts from the 
Republic of South Africa where patient records could be linked to the vital registry. We 
excluded individuals from the Asia-Pacific region (20) (N=849) as the number of deaths was 
very low, those from Mexico because of having too few eligible participants (N=100) and 
those from Argentina (N=545) as mortality was reported to be under-ascertained and no 
further corrections could be applied.  
 
Ascertainment of mortality 
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The primary outcome was death due to any cause in the 48 months after ART initiation. To 
address concerns regarding death under-ascertainment, a survey addressing ascertainment 
and matching with external mortality registries was distributed. Seventy-five percent of 
cohorts in Europe reported good or very good death ascertainment, but only 40% conducted 
cross-checks with mortality registries. Cumulative mortality in the European cohorts did not 
vary significantly according to self-assessment of mortality ascertainment (data not shown). . 
Death ascertainment was reported to be poor in East and West Africa. To correct mortality 
estimates for East Africa, we used an inverse-probability-weighted estimator of the mortality 
rate where weights are constant and equal to the inverse ratio of the patients who could be 
traced out of all patients who were lost to follow-up (21). For corrections of under-
ascertainment in West Africa, we used a modification of the approach by Brinkhof and 
colleagues (22), which uses inflation factors to account for mortality under-reporting, under 
the assumption that mortality under-ascertainment was similar in the two regions (21). Death 
rates based on observed data were estimated for different participant subgroups. These 
‘passive’ mortality estimates were then multiplied by a group-specific inflation factor 
determined as the ratio of the lost-to-follow-up-adjusted death rates over the observed rates 
estimated within East African cohorts (21-22). For the Republic of South Africa cohort, civil 
identification numbers, where available, were cross-checked with national population 
registers prior to data transfer to confirm dates of death. All sites in the Caribbean, Central 
and South America region, except for Argentina, reported ascertaining deaths with 
population-based mortality registries. North American cohorts link to a population-based 
death registry at least annually. 
 
Statistical methods 
Data-contributing regions were categorized as Europe; East Africa; West Africa; Southern 
Africa; South America; North America; and Central America and the Caribbean. The 
countries in each region are shown in Supplemental Table 1.  
 
Participant characteristics at ART initiation by region were described using frequency tables 
for categorical variables and medians and interquartile ranges for continuous variables. 
Differences in socio-demographic and clinical characteristics by region were assessed with 
Kruskal-Wallis test for continuous variables and the chi-squared test for independence for 
categorical variables. We assumed that women from Haiti, Republic of South Africa, West 
Africa and East Africa with unknown transmission mode were infected through heterosexual 
contact (1). 
 
Mortality rates were calculated by region for the intervals 0-3, 3-6, 6-12, 12-24 and 24-48 
months after ART initiation. Mortality rate ratios, compared to Europe, were estimated at 
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each interval using a piecewise exponential parametric survival model fit through Poisson 
regression. The use of a piecewise exponential parametric survival model fit through Poisson 
regression simplified the prediction of mortality rate ratios for each duration interval on ART, 
while the implicit assumption of constant hazards within each interval produced almost 
identical inter-regional comparative mortality rate ratio estimates when compared to a 
piecewise spline-based flexible parametric survival model (23-24). Parametric survival 
models offer alternatives and may be more appropriate than semi-parametric techniques 
such a Cox regression when the proportional hazards assumption is in question (25). 
Multivariable models were adjusted for baseline age (<30, 30-44, 45-59, ≥60 years), CD4 cell 
counts within 6 months prior to ART initiation (0-24, 25-49, 50-99, 100-199, 200-349, ≥350 
cells/mm3, unknown) and period of ART initiation (2000-2003, 2004-2007, 2008-2011, 2012-
2014). As the HIV epidemics in East, West and South Africa, the Caribbean, South and 
Central America are predominantly heterosexual epidemics, no adjustment for transmission 
category could be applied for comparisons between these regions and Europe or North 
America. Neither adjustment for HIV-RNA nor AIDS prior to ART initiation were included 
because of the high percentage of missing values in these regions. For comparisons 
between North America and Europe, multivariable models were additionally adjusted for 
transmission category, HIV-RNA, AIDS at ART initiation, and race/ethnicity in the subset of 
participants with available information for these variables. 
 
A set of sensitivity analyses were undertaken. Analyses were repeated restricting to (i) 
patients with documented or presumed heterosexual transmission, (ii) patients starting ART 
post-2004, (iii) cohorts with >50% of data on CD4 cell counts at baseline, and (iv) cohorts 
with “very good” self-reported mortality ascertainment.  
 
Statistical analyses were performed using Stata 14 (StataCorp, College Station, Texas, 
USA).  
 
 
RESULTS 
A total of 190,175 women (16% Europe, 47% East Africa, 13% West Africa, 19% South 
Africa, 1% South America, 3% North America and 2% Central America/Caribbean) were 
included. Median age at ART initiation ranged from 33 years in South Africa to 40 years in 
North America. The proportion of persons who injected drugs was highest in North America 
(18%) and Europe (7%). Only 16% of the women in North America were of white 
race/ethnicity, while 63% and 17% were of Black race and Hispanic ethnicity, respectively. 
Race/ethnicity data were available for 45% of European women, 26% of whom were Black, 
largely migrants from Sub-Saharan Africa. Of ART initiators, median CD4 cell counts at 
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initiation were close to 250 cells/mm3 in Europe and North America, 141 cells/mm3 in South 
Africa and 170-190 cells/mm3 in other regions (Table 1).  
 
In all regions except for North America, due to cohort inclusion criteria in that region, the 
highest death rates occurred during the first 3 months after starting ART and declined 
thereafter (Figure 1). Women from Europe had the lowest death rates across the study 
period, whereas the highest were observed among women from Central America and the 
Caribbean between 0-3 months, in East Africa between 3-6 months and West Africa between 
6-48 months from ART initiation.  
 
Mortality rates in women from Europe were significantly lower than rates in women from all 
other regions during the first 48 months after starting ART, except for North American 
women, whose rates were similar for the first 6 months and significantly higher thereafter 
(Table 2). The greatest differences were observed in the first 3 months and attenuated 
thereafter. Taking into account differences in baseline age, CD4 cell count and period of ART 
initiation, differences in mortality were attenuated although still of large magnitude and 
statistically significant. After additional adjustments for transmission category, HIV-RNA and 
AIDS prior to ART initiation for comparisons between North America and Europe, differences 
in mortality were reduced, but still present. Further adjustment for race/ethnicity in the subset 
of patients with available information for this variable contributed to reduction of differences 
between 6 and 48 months on ART.  
 
Sensitivity analyses yielded results consistent with the main analyses (Supplemental Table 
2).  
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DISCUSSION  
 
This large collaborative study found that there was significant variability in all-cause mortality 
among WLWH in Europe, the Americas and Sub-Saharan Africa up to 48 months after ART 
initiation, with distinct geographical patterns for short-, mid- and long-term mortality. The 
highest mortality was observed in WLWH in Central America and the Caribbean and Sub-
Saharan Africa, who also had the lowest CD4 counts at ART initiation. The lowest mortality 
was reported in women living in Europe, who had, together with women from North America, 
the highest CD4 counts; women living in South America had intermediate mortality. These 
differences were apparent after correcting for under-ascertainment in mortality in most of the 
African sites. Mortality was highest in the first three months after ART initiation in all 
evaluable regions, and decreased from then onwards to reach stable rates from the first until 
the fourth year following ART, when inter-regional differences were attenuated.  
 
The baseline differences of WLWH explained some of the relative differences encountered 
but did not fully explain the higher mortality observed in women from Sub-Saharan African 
and American regions compared to the women on ART living in Europe. Indeed, women from 
Sub-Saharan Africa and from Central America and the Caribbean had the lowest CD4 counts 
at ART initiation, a strong predictor of subsequent HIV-related, mortality (8-11, 26). Median 
CD4 counts at ART initiation were close to 250 cells/mm3 in women living in North America 
and Europe, but mortality rates differed substantially. The lower mortality of WLWH in Europe 
compared to women in North America has been previously reported (8, 9) and attributed to 
the accessibility and equity of health services, to background mortality rates, to causes of 
death of populations affected by HIV in the different settings, and to near complete death 
ascertainment in North America (27). Our findings build on these explanations expanding 
comparisons to East and West Africa, the Caribbean, Central and South and America.  
 
Most of the European countries included in this study have universal health care systems, 
which grant free access to HIV testing, HIV care and ART medications, and this may account 
for some of the better HIV-related outcomes observed among women in European cohorts. 
However, not all countries in Europe provide free access to ART for undocumented migrants, 
a non-negligible proportion of WLWH in Europe (28-29). Even for documented migrant 
women, barriers to access care due to socio-economic, gender, ethnic and cultural factors 
exist and may have a negative impact on survival (30). Barriers to accessing adequate 
healthcare have been consistently reported in Black and Latina women and First 
Nations/indigenous women in North America, irrespective of HIV status (10, 30-33). In 
addition, access to HIV testing and life-saving ART among women from low and middle -
income settings is considerably lower than in Western Europe and North America (1-2, 34). 
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These health inequities may lead to lower CD4 counts at ART initiation, which likely account 
for the exceedingly high early and overall mortality observed in the women in Sub-Saharan 
Africa and Central and South America and the Caribbean. 
 
Our findings need to be placed in the context of background mortality rates of women from 
the general population living in geographical regions with generalized HIV epidemics, 
together with mortality patterns of racial and ethnic minorities in North America and Europe, 
with concentrated HIV epidemics (1, 35-36). Globally, all-cause mortality in women living in 
Sub-Saharan Africa, the Caribbean, and Central and South America is also higher than 
among the women from Europe and North America (13). Within North America, African-
American and Latina women have higher mortality rates than white women, both in general 
(35-36) and from HIV-infection (31), but patterns have been described to be complex and 
evolve over time (37). Conversely, migrant women in Europe have lower all-cause mortality 
relative to general population women, consistent with healthy migrant selection bias (38). 
 
For all regions analyzed, and with different magnitudes, mortality was highest in the initial 
three months following ART. The exception to this pattern was North America given NA-ACCORD’s 
inclusion criteria, as anyone who died very soon after enrollment (including those who initiated ART) 
was excluded, thereby artificially reducing early mortality in North America. Higher mortality soon 
after ART has been well described and attributed to late ART initiation and is largely caused 
by AIDS-defining conditions preventable with ART (39-42). Failures in earlier HIV testing 
and/or linkage to care to commence ART represent a clear opportunity for intervention. 
Unfortunately, cause of death was not available in our dataset for most settings, but studies 
that have analyzed causes of death patterns report that, for both AIDS and non-AIDS 
defining causes of death, rates are lower in WLWH in Europe than in North America (10).  
 
These analyses have been performed in the largest and most globally representative sample 
assembled to date of WLWH. Data from 56 countries in seven multi-site cohort collaborations 
have been harmonized to reach a final sample of nearly 200,000 women initiating ART and 
under follow-up. Inevitably, selection and information biases were likely to be present, and 
multiple strategies were used to minimize their effects. Stringent inclusion criteria were 
required leading to the exclusion of Asia Pacific cohort, Central Africa and some countries 
within Central and South America (14-19). Under-ascertainment of mortality at clinical sites in 
East and West Africa were partially corrected by a modification of Brinkhof and colleagues’ 
approach (21-22, 43-44). However, under-reporting is likely to be time-sensitive in sites in 
Sub-Saharan Africa and is also likely to increase overtime. .  
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Sensitivity analyses to account for potential selection biases derived from lack of cross-
checks with mortality registries in some of the European cohorts, and of differential data 
availability to characterize losses to follow-up were also performed. Unfortunately, having 
missing data was inevitable in such an ambitious data collection and harmonization exercise. 
For example, information on CD4 count and HIV-RNA viral load was missing for a large 
proportion of the women from lower-income settings and reveals the lack of availability of 
clinical monitoring tools in those regions. Type of ART regimen was not available from all 
sites, and given that the study period started in 2000, we assumed all the women to be on at 
least 3 antiretroviral drugs. While mortality of women living with HIV in Europe may be under-
ascertained, this was assessed through sensitivity analyses that excluded cohorts that did 
not perform cross-checks with mortality registries and/or reported incomplete or poor death 
ascertainment, and the main findings did not significantly change. A recent publication 
highlights that European cohort participants were generally representative of the national 
HIV-diagnosed population reported by surveillance systems, but that PWID, migrants, 
persons with low CD4 counts and those over 55 years of age are generally under-
represented in European cohorts (45). Finally, As of today, national ART guidelines have 
expanded in most settings to 'Treat All' patients with HIV, regardless of CD4 count or clinical 
stage, as recommended by WHO in 2015. While we have controlled for baseline AIDS status 
and CD4 count, it is possible that differences in ART guidelines between regions, which in 
part determine who initiates ART, could explain some of the differences observed. 
 
The global health inequalities highlighted in this study pertain to women who have accessed 
health services and have started ART, so they are likely to underestimate overall gaps for 
women living with HIV, particularly those not yet diagnosed or linked to care. Voluntary 
antenatal HIV testing, widely implemented in most countries included in these analyses, has 
been a major step forward in increasing access to health services, but requires expansion 
and improvement. The data presented can support the development of context-specific 
interventions to help countries reach their 2020 targets and improve the life expectancies of 
HIV-positive women at the global level. 
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Mwebesa Bosco Bwana (Mbarara University of Science and Technology (MUST), Mbarara, Uganda), 
Barbara Castelnuovo (Infectious Diseases Institute (IDI), Kampala, Uganda),  Fred Nalugoda (Rakai 
Health Sciences Program (RHSP), Kalisizo, Uganda), Geoffrey Somi (National AIDS Control Program 
(NACP) Dar es Salaam, Tanzania), and Mark Urassa (National Institute for Medical Research (NIMR), 
Mwanza, Tanzania), Batya Elul (Columbia University, New York, USA), Jennifer Syvertsen (University 
of California Riverside, California, USA) Rami Kantor (Brown University, Providence, USA), Jeff Martin 
(University of California, San Francisco, USA), Craig Cohen (University of California, San Fransisco, 
USA), Paula Braitstein (University of Toronto, Toronto, Canada)  East African IeDEA Regional Data 
Center, Indiana University: Kara Wools-Kaloustian, Constantin Yiannoutsos, and Beverly Musick.    
Funding: Research reported in this publication was supported by the National Institute Of Allergy And 
Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute Of Child Health & Human 
Development (NICHD), National Institute On Drug Abuse (NIDA), National Cancer Institute (NCI), and 
the National Institute of Mental Health (NIMH), in accordance with the regulatory requirements of the 
National Institutes of Health under Award Number U01AI069911 East Africa IeDEA Consortium. The 
content is solely the responsibility of the authors and does not necessarily represent the official views 
of the National Institutes of Health. 
 
IeDEA-WA Steering Group 
Site investigators and cohorts: Adult cohorts: Marcel Djimon Zannou, CNHU, Cotonou, Benin; Armel 
Poda, CHU Souro Sanou, Bobo Dioulasso, Burkina Faso; Fred Stephen Sarfo and Komfo Anokeye 
Teaching Hospital, Kumasi, Ghana; Eugene Messou, ACONDA CePReF, Abidjan, Cote d’Ivoire; Henri 
Chenal, CIRBA, Abidjan, Cote d’Ivoire; Kla Albert Minga, CNTS, Abidjan, Cote d’Ivoire; Emmanuel 
Bissagnene, and Aristophane Tanon, CHU Treichville, Cote d’Ivoire; Moussa Seydi, CHU de Fann, 
Dakar, Senegal; Akessiwe Akouda Patassi, CHU Sylvanus Olympio, Lomé, Togo. Pediatric cohorts: 
Sikiratou Adouni Koumakpai-Adeothy,_CNHU, Cotonou, Benin; Lorna Awo Renner, Korle Bu Hospital, 
Accra, Ghana; Sylvie Marie N’Gbeche, ACONDA CePReF, Abidjan, Ivory Coast; Clarisse Amani 
Bosse, ACONDA_MTCT+, Abidjan, Ivory Coast; Kouadio Kouakou, CIRBA, Abidjan, Cote d’Ivoire; 
Madeleine Amorissani Folquet, CHU de Cocody, Abidjan, Cote d’Ivoire; François Tanoh Eboua, CHU 
de Yopougon, Abidjan, Cote d’Ivoire; Fatoumata Dicko Traore, Hopital Gabriel Toure, Bamako, Mali; 
Elom Takassi, CHU Sylvanus Olympio, Lomé,Togo; Coordinators and data centers: François Dabis, 
Elise Arrive, Eric Balestre, Renaud Becquet, Charlotte Bernard, Shino Chassagne Arikawa, Alexandra 
Doring, Antoine Jaquet, Karen Malateste, Elodie Rabourdin, Thierry Tiendrebeogo, ADERA, Isped & 
Published in final edited form as: AIDS. 2019 Oct 11. doi: 10.1097/QAD.0000000000002399 
13 
 
INSERM U1219, Bordeaux, France. Sophie Desmonde, Julie Jesson, Valeriane Leroy, Inserm 1027, 
Toulouse, France. Didier Koumavi Ekouevi, Jean-Claude Azani, Patrick Coffie, Abdoulaye Cissé, Guy 
Gnepa, Apollinaire Horo, Christian Kouadio, Boris Tchounga, PACCI, CHU Treichville, Abidjan, Côte 
d’Ivoire. 
Funding: The IeDEA West Africa collaboration was supported by the National Institute of Mental 
Health (NIMH), National Cancer Institute (NCI), the Eunice Kennedy Shriver National Institute of Child 
Health & Human Development (NICHD), and the National Institute of Allergy and Infectious Diseases 
(NIAID) of the U.S. National Institutes of Health (NIH) under Award Number U01AI069919. The 
content is solely the responsibility of the authors and does not necessarily represent the official views 
of the National Institutes of Health. 
 
IeDEA-CA Steering Group 
Nimbona Pélagie, ANSS, Burundi; Patrick Gateretse, Jeanine Munezero, Valentin Nitereka, Théodore 
Niyongabo, Christelle Twizere, Centre National de Reference en Matiere de VIH/SIDA, Burundi; 
Hélène Bukuru, Thierry Nahimana, CHUK, Burundi; Jérémie Biziragusenyuka, Risase Scholastique 
Manyundo, HPRC, Burundi; Tabeyang Mbuh, Kinge Thompson Njie, Edmond Tchassem, Kien-Atsu 
Tsi, Bamenda Hospital, Cameroon; Rogers Ajeh, Mark Benwi, Anastase Dzudie, Akindeh Mbuh, Marc 
Lionel Ngamani, Victorine Nkome, CRENC & Douala General Hospital, Cameroon; Djenabou 
Amadou, Eric Ngassam, Eric Walter Pefura Yone, Jamot Hospital, Cameroon; Alice Ndelle Ewanoge, 
Norbert Fuhngwa, Chris Moki, Denis Nsame Nforniwe, Limbe Regional Hospital, Cameroon; Catherine 
Akele, Faustin Kitetele, Patricia Lelo, Martine Tabala, Kalembelembe Pediatric Hospital, Democratic 
Republic of Congo; Emile Wemakoy Okitolonda, Landry Wenzi, Kinshasa School of Public Health, 
Democratic Republic of Congo; Merlin Diafouka, Martin Herbas Ekat, Dominique Mahambou Nsonde, 
CTA Brazzaville, Republic of Congo; Adolphe Mafou, CTA Pointe-Noire, Republic of Congo; Fidele 
Ntarambirwa, Bethsaida Hospital, Rwanda; Yvonne Tuyishimire, Busanza Health Center, Rwanda; 
Theogene Hakizimana, Gahanga Health Center, Rwanda; Josephine Ayinkamiye, Gikondo Health 
Center, Rwanda; Sandrine Mukantwali, Kabuga Health Center, Rwanda; Henriette Kayitesi, Olive 
Uwamahoro, Kicukiro Health Center, Rwanda; Viateur Habumuremyi, Jules Ndumuhire, Masaka 
Health Center, Rwanda; Joyce Mukamana, Yvette Ndoli, Oliver Uwamahoro, Nyarugunga Health 
Center, Rwanda; Gallican Kubwimana, Pacifique Mugenzi, Benjamin Muhoza, Athanase Munyaneza, 
Emmanuel Ndahiro, Diane Nyiransabimana, Jean d'Amour Sinayobye, Vincent Sugira, Rwanda 
Military Hospital, Rwanda; Chantal Benekigeri, Gilbert Mbaraga, WE-ACTx Health Center, Rwanda.  
Coordinating and Data Centers:  
Adebola Adedimeji, Kathryn Anastos, Madeline Dilorenzo, Lynn Murchison, Jonathan Ross, Albert 
Einstein College of Medicine, USA; Diane Addison, Margaret Baker, Ellen Brazier, Heidi Jones, 
Elizabeth Kelvin, Sarah Kulkarni, Grace Liu, Denis Nash, Matthew Romo, Olga Tymejczyk, Institute for 
Implementation Science in Population Health, Graduate School of Public Health and Health Policy, 
City University of New York (CUNY), USA; Batya Elul, Columbia University, USA; Xiatao Cai, Don 
Hoover, Hae-Young Kim, Chunshan Li, Qiuhu Shi, Data Solutions, USA; Robert Agler, Kathryn 
Lancaster, Marcel Yotebieng, Ohio State University, USA; Mark Kuniholm, University at Albany, State 
University of New York, USA; Andrew Edmonds, Angela Parcesepe, University of North Carolina at 
Chapel Hill, USA; Olivia Keiser, University of Geneva; Stephany Duda; Vanderbilt University School of 
Medicine, USA; April Kimmel, Virginia Commonwealth University School of Medicine, USA; Margaret 
McNairy, Weill Cornell Medical Center.  
Funding: National Institute of Allergy and Infectious Diseases of the National Institutes of Health 
under Award Number U01AI096299 (PI: Anastos and Nash). 
 
IeDEA-Asia Pacific Steering Group 
PS Ly* and V Khol, National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; FJ 
Zhang*, HX Zhao and N Han, Beijing Ditan Hospital, Capital Medical University, Beijing, China; MP 
Lee*, PCK Li, W Lam and YT Chan, Queen Elizabeth Hospital, Hong Kong, China; N Kumarasamy*‡, 
S Saghayam and C Ezhilarasi, Chennai Antiviral Research and Treatment Clinical Research Site 
(CART CRS), YRGCARE Medical Centre, VHS, Chennai, India; S Pujari*, K Joshi , S Gaikwad and A 
Chitalikar, Institute of Infectious Diseases, Pune, India; TP Merati*, DN Wirawan and F Yuliana, 
Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia; E Yunihastuti*, D Imran 
and A Widhani, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General 
Hospital, Jakarta, Indonesia; J Tanuma*, S Oka and T Nishijima, National Center for Global Health 
and Medicine, Tokyo, Japan; JY Choi*, S Na and JH Kim, Division of Infectious Diseases, Department 
of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; BLH Sim*, YM Gani, 
Published in final edited form as: AIDS. 2019 Oct 11. doi: 10.1097/QAD.0000000000002399 
14 
 
and R David, Hospital Sungai Buloh, Sungai Buloh, Malaysia; A Kamarulzaman*, SF Syed Omar, S 
Ponnampalavanar and I Azwa, University Malaya Medical Centre, Kuala Lumpur, Malaysia; R 
Ditangco*, M Pasayan and R Bantique, Research Institute for Tropical Medicine, Manila, Philippines; 
YJ Chan*, WW Ku and PC Wu, Taipei Veterans General Hospital, Taipei, Taiwan; OT Ng*†, PL Lim, 
LS Lee and Z Ferdous, Tan Tock Seng Hospital, Singapore; A Avihingsanon*,  S Gatechompol, P 
Phanuphak and C Phadungphon, HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, 
Thailand; S Kiertiburanakul*, A Phuphuakrat, L Chumla and N Sanmeema, Faculty of Medicine 
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; R Chaiwarith*, T Sirisanthana, W 
Kotarathititum and J Praparattanapan, Research Institute for Health Sciences, Chiang Mai, Thailand; 
S Khusuwan* and P Kambua, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; KV Nguyen*, 
HV Bui, DTH Nguyen and DT Nguyen, National Hospital for Tropical Diseases, Hanoi, Vietnam; DD 
Cuong*, NV An and NT Luan, Bach Mai Hospital, Hanoi, Vietnam; AH Sohn*, JL Ross* and B 
Petersen, TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; MG Law*, A 
Jiamsakul* and R Bijker, The Kirby Institute, UNSW Australia, Sydney, Australia. 
* TAHOD Steering Committee member;  † Steering Committee Chair;  ‡ co-Chair. 
 
The TREAT Asia HIV Observational Database is an initiative of TREAT Asia, a program of amfAR, 
The Foundation for AIDS Research, with support from the U.S. National Institutes of Health’s National 
Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, 
and the National Institute on Drug Abuse, as part of the International Epidemiology Databases to 
Evaluate AIDS (IeDEA; U01AI069907).  The Kirby Institute is funded by the Australian Government 
Department of Health and Ageing, and is affiliated with the Faculty of Medicine, UNSW Sydney.  The 
content of this publication is solely the responsibility of the authors and does not necessarily represent 
the official views of any of the governments or institutions mentioned above. 
 
 
IeDEA Caribbean, Central, and South America (CCASAnet) Steering Group 
Fundación Huésped, Argentina: Pedro Cahn, Carina Cesar, Valeria Fink, Omar Sued, Emanuel 
Dell’Isola, Hector Perez, Jose Valiente, Cleyton Yamamoto. Instituto Nacional de Infectologia-Fiocruz, 
Brazil: Beatriz Grinsztejn, Valdilea Veloso, Paula Luz, Raquel de Boni, Sandra Cardoso Wagner, Ruth 
Friedman, Ronaldo Moreira. Universidade Federal de Minas Gerais, Brazil: Jorge Pinto, Flavia 
Ferreira, Marcelle Maia. Universidade Federal de São Paulo, Brazil: Regina Célia de Menezes Succi, 
Daisy Maria Machado, Aida de Fátima Barbosa Gouvêa. Fundación Arriarán, Chile: Marcelo Wolff, 
Claudia Cortes, Maria Fernanda Rodriguez, Gladys Allendes.Les Centres GHESKIO, Haiti: Jean 
William Pape, Vanessa Rouzier, Adias Marcelin, Christian Perodin. Hospital Escuela Universitario, 
Honduras: Marco Tulio Luque. Instituto Hondureño de Seguridad Social, Honduras: Denis 
Padgett. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico: Juan Sierra 
Madero, Brenda Crabtree Ramirez, Paco Belaunzaran, Yanink Caro Vega. Instituto de Medicina 
Tropical Alexander von Humboldt, Peru: Eduardo Gotuzzo, Fernando Mejia, Gabriela 
Carriquiry. Vanderbilt University Medical Center, USA: Catherine C McGowan, Bryan E Shepherd, 
Timothy Sterling, Karu Jayathilake, Anna K Person, Peter F Rebeiro, Jessica Castilho, Stephany N 
Duda, Fernanda Maruri, Hilary Vansell, Cathy Jenkins, Ahra Kim, Sarah Lotspeich. 
Funding: IeDEA CCASAnet: This work was supported by the NIH-funded Caribbean, Central and 
South America network for HIV epidemiology (CCASAnet), a member cohort of the International 
Epidemiologic Databases to Evaluate AIDS (leDEA) (U01AI069923). This award is funded by the 
following institutes: Eunice Kennedy Shriver National Institute Of Child Health & Human Development 
(NICHD), Office Of The Director, National Institutes Of Health (OD), National Institute Of Allergy And 
Infectious Diseases (NIAID), National Cancer Institute (NCI), and the National Institute Of Mental 
Health (NIMH). Peter Rebeiro is supported by K01AI131895, “The HIV Care Continuum and Health 
Policy: Changes Through Context and Geography” Paula Luz is supported by funding from the 
National Council of Technological and Scientific Development (CNPq) and the Research Funding 
Agency of the State of Rio de Janeiro (FAPERJ) 
 
 
NA-ACCORD Steering Group 
Executive Committee: Richard D. Moore, Michael S. Saag, Stephen J. Gange, Mari M. Kitahata, Keri 
N. Althoff, Michael A. Horberg, Marina B. Klein, Rosemary G. McKaig and Aimee M. Freeman 
Data Management Core: Mari M. Kitahata, Stephen E. Van Rompaey, Heidi M. Crane, Daniel R. 
Drozd, Liz Morton, Justin McReynolds and William B. Lober 
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Epidemiology and Biostatistics Core: Stephen J. Gange, Keri N. Althoff, Jennifer S. Lee, Bin You, 
Brenna Hogan, Jinbing Zhang, Jerry Jing, Elizabeth Humes, and Sally Coburn. AIDS Clinical Trials 
Group Longitudinal Linked Randomized Trials: Constance A. Benson and Ronald J. Bosch. AIDS Link 
to the IntraVenous Experience: Gregory D. Kirk. Fenway Health HIV Cohort: Kenneth H. Mayer and 
Chris Grasso. HAART Observational Medical Evaluation and Research: Robert S. Hogg, P. Richard 
Harrigan, Julio SG Montaner, Benita Yip, Julia Zhu, Kate Salters and Karyn Gabler. HIV Outpatient 
Study: Kate Buchacz and Jun Li. HIV Research Network: Kelly A. Gebo and Richard D. Moore. Johns 
Hopkins HIV Clinical Cohort: Richard D. Moore. John T. Carey Special Immunology Unit Patient Care 
and Research Database, Case Western Reserve University: Benigno Rodriguez. Kaiser Permanente 
Mid-Atlantic States: Michael A. Horberg. Kaiser Permanente Northern California: Michael J. Silverberg 
Longitudinal Study of Ocular Complications of AIDS: Jennifer E. Thorne. Multicenter Hemophilia 
Cohort Study–II: Charles Rabkin. Multicenter AIDS Cohort Study: Joseph B. Margolick, Lisa P. 
Jacobson and Gypsyamber D’Souza. Montreal Chest Institute Immunodeficiency Service Cohort: 
Marina B. Klein. Ontario HIV Treatment Network Cohort Study: Abigail Kroch, Ann Burchell, Adrian 
Betts and Joanne Lindsay. Retrovirus Research Center, Bayamon Puerto Rico:  Robert F. Hunter-
Mellado and Angel M. Mayor. Southern Alberta Clinic Cohort: M. John Gill. Study of the 
Consequences of the Protease Inhibitor Era: Steven G. Deeks and Jeffrey N. Martin. Study to 
Understand the Natural History of HIV/AIDS in the Era of Effective Therapy: Jun Li and John T. Brooks 
University of Alabama at Birmingham 1917 Clinic Cohort: Michael S. Saag, Michael J. Mugavero and 
James Willig. University of California at San Diego: William C. Mathews. University of North Carolina 
at Chapel Hill HIV Clinic Cohort: Joseph J. Eron and Sonia Napravnik. University of Washington HIV 
Cohort: Mari M. Kitahata, Heidi M. Crane and Daniel R. Drozd. Vanderbilt Comprehensive Care Clinic 
HIV Cohort: Timothy R. Sterling, David Haas, Peter Rebeiro and Megan Turner. Veterans Aging 
Cohort Study: Amy C. Justice, Robert Dubrow, and David Fiellin. Women's Interagency HIV Study: 
Stephen J. Gange and Kathryn Anastos 
Funding: This work was supported by National Institutes of Health grants 
U01AI069918, F31AI124794, F31DA037788,G12MD007583,1AI093197, K01AI131895, K23EY01370,  
K24AI065298, K24AI118591, K24DA000432, KL2TR000421,M01RR000052,N01CP01004,N02CP055
504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050410, 
P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01CA165937, R01DA011602, 
R01DA012568, R01 AG053100, R24AI067039, U01AA013566, U01AA020790, U01AI031834, 
U01AI034989, U01AI034993, U01AI034994, U01AI035004, U01AI035039,U01AI035040,  
U01AI035041, U01AI035042, U01AI037613, U01AI037984, U01AI038855, U01AI038858, 
U01AI042590, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01AI103390, 
U01AI103397, U01AI103401, U01AI103408, U01DA03629, U01DA036935, U01HD032632, 
U10EY008057, U10EY008052, U10EY008067, U24AA020794,U54MD007587, UL1RR024131, 
UL1TR000004, UL1TR000083, UL1TR000454, UM1AI035043, Z01CP010214 and Z01CP010176; 
contracts CDC-200-2006-18797 and CDC-200-2015-63931 from the Centers for Disease Control and 
Prevention, USA; contract 90047713 from the Agency for Healthcare Research and Quality, USA; 
contract 90051652 from the Health Resources and Services Administration, USA; grants CBR-86906, 
CBR-94036, HCP-97105 and TGF-96118 from the Canadian Institutes of Health Research, Canada; 
Ontario Ministry of Health and Long Term Care; and the Government of Alberta, Canada. Additional 
support was provided by the National Cancer Institute, National Institute for Mental Health and 
National Institute on Drug Abuse.  
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Table 1. Characteristics of 190,175 women living with HIV in Europe, sub-Saharan Africa and the Americas who initiated ART 2000-2014 
 Europe East Africa West Africa South Africa South 
America 
North America Central 
America and 
Caribbean 
Participants included [n (%)] 30313 (15.9) 
 
88840 (46.7) 24920 (13.1) 35612 (18.7) 1517 (0.8) 4801 (2.5) 4172 (2.2) 
Age, years [Median (IQR)] 
   <30 
   30 – 44 
   45 – 59 
   ≥60 
35 (29 – 42) 
8795 (29.0) 
15973 (52.7) 
4666 (15.4) 
879 (2.9) 
34 (29 – 41) 
27514 (31.0) 
46514 (52.4) 
13190 (14.8) 
1622 (1.8) 
34 (29 – 41) 
7178 (28.8) 
13936 (55.9) 
3454 (13.9) 
352 (1.4) 
33 (28 – 40) 
12038 (33.8) 
18865 (53.0) 
4384 (12.3) 
325 (0.9) 
35 (29 – 43) 
437 (28.8) 
773 (51.0) 
271 (17.9) 
36 (2.4) 
40 (33 – 47) 
844 (17.6) 
2433 (50.7) 
1384 (28.8) 
140 (2.9) 
36 (30 – 44) 
1057 (25.3) 
2196 (52.6) 
816 (19.6) 
103 (2.5) 
Mode of transmission [n (%)] 
   Heterosexual 
   IDU 
 
28324 (93.4) 
1989 (6.6) 
 
88832 (99.99) 
8 (0.01) 
 
24920 (100.0) 
0 
 
35612 (100.0) 
0 
 
1510 (99.5) 
7 (0.5) 
 
3925 (81.7) 
876 (18.3) 
 
4171 (99.98) 
1 (0.02) 
CD4 T-cell counts, cells/l 
   Median (IQR) 
   0-24 
   25-49 
   50-99 
   100-199 
   200-349 
   ≥350 
   Unknown 
 
248 (140–361) 
1739 (5.7) 
1134 (3.7) 
2109 (7.0) 
5314 (17.5) 
9604 (31.7) 
7402 (24.4) 
3011 (9.9) 
 
172 (83-270) 
6478 (7.3) 
5013 (5.6) 
9730 (10.9) 
21249 (23.9) 
20811 (23.4) 
8904 (10.0) 
16655 (18.7) 
 
168 (74 – 289) 
691 (2.8) 
422 (1.7) 
780 (3.1) 
1589 (6.4) 
1466 (5.9) 
1036 (4.2) 
18936 (76.0) 
 
141 (69-208) 
2917 (8.2) 
2611 (7.3) 
5028 (14.1) 
11013 (30.9) 
7121 (20.0) 
1121 (3.1) 
5801 (16.3) 
 
191 (74-297) 
123 (8.1) 
106 (7.0) 
173 (11.4) 
264 (17.4) 
426 (28.1) 
189 (12.5) 
236 (15.6) 
 
246 (115-372) 
457 (9.5) 
193 (4.0) 
318 (6.6) 
759 (15.8) 
1369 (28.5) 
1210 (25.2) 
495 (10.3) 
 
168 (80-252) 
313 (7.5) 
295 (7.1) 
527 (12.6) 
1159 (27.8) 
1242 (29.8) 
215 (5.1) 
421 (10.1) 
Year of ART initiation 
   2000-2003 
   2004-2007 
   2008-2011 
   2012-2014 
 
8043 (26.5) 
9959 (32.8) 
9535 (31.5) 
2776 (9.2) 
 
907 (1.0) 
25399 (28.6) 
37573 (42.3) 
24961 (28.1) 
 
1519 (6.1) 
9165 (36.8) 
10078 (40.0) 
4158 (16.7) 
 
563 (1.6) 
11859 (33.3) 
16488 (46.3) 
6702 (18.8) 
 
188 (12.4) 
440 (29.0) 
621 (40.9) 
268 (17.7) 
 
1440 (30.0) 
1592 (33.2) 
1749 (36.4) 
20 (0.4) 
 
502 (12.0) 
1306 (31.3) 
2341 (56.1) 
23 (0.6) 
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Table 2. Mortality rate ratios (95% CI) compared to Europe by duration on antiretroviral therapy 
Mortality rate ratio Duration on ART (months) 
0 – 3 3 - 6 6 - 12 12 - 24 24 - 48 
East Africa 
Non corrected 3.74 (3.08 – 4.54) 2.25 (1.81 – 2.81) 1.89 (1.54 – 2.33) 1.41 (1.18 – 1.67) 1.04 (0.89 – 1.22) 
Corrected1 8.25 (6.69 – 10.17) 4.76 (3.71 – 6.11) 4.73 (3.74 – 5.98) 4.33 (3.58 – 5.24) 4.10 (3.45 – 4.88) 
Corrected and adjusted for baseline 
patient characteristics2 
7.25 (5.87 – 8.97) 4.24 (3.30 – 5.46) 4.24 (3.35 – 5.37) 3.89 (3.21 – 4.72) 3.63 (3.04 – 4.33) 
      
West Africa      
Non corrected  4.22 (3.42 – 5.21) 2.00 (1.55 – 2.60) 1.98 (1.55 – 2.52) 1.95 (1.61 – 2.36) 1.59 (1.33 – 1.90) 
Corrected3 9.30 (7.63 – 11.32) 4.23 (3.36 – 5.34) 4.94 (4.00 – 6.11) 6.01 (5.09 – 7.09) 6.28 (5.43 – 7.26) 
Corrected and adjusted by age at 
ART initiation 
9.73 (7.99 – 11.85) 4.50 (3.57 – 5.67) 5.10 (4.12 – 6.31) 6.09 (5.16 – 7.19) 6.42 (5.55 – 7.43) 
Corrected and adjusted by age and 
period of ART initiation 
8.95 (7.34 – 10.91) 4.05 (3.21 – 5.11) 4.38 (3.54 – 5.43) 5.37 (4.54 – 6.35) 5.61 (4.84 – 6.51) 
Corrected and adjusted by  age, 
period of ART initiation and CD4 in 
patients with available CD4 
3.42 (2.53 – 4.62) 1.44 (0.94 – 2.19) 2.07 (1.46 – 2.94) 2.42 (1.86 – 3.15) 2.49 (1.98 – 3.14) 
      
South Africa      
Crude 6.25 (5.13 – 7.62) 3.63 (2.89 – 4.56) 4.37 (3.54 – 5.39) 3.57 (3.01 – 4.24) 4.16 (3.57 – 4.83) 
Adjusted for baseline patient 
characteristics2 
5.42 (4.43 – 6.64) 3.15 (2.50 – 3.97) 3.77 (3.05 – 4.67) 3.05 (2.56 – 3.63) 3.47 (2.97 – 4.06) 
      
South America      
Crude 5.19 (3.45 – 7.81) 1.93 (0.98 – 3.83) 3.13 (1.88 – 5.22) 1.95 (1.19 – 3.22) 2.84 (1.93 – 4.16) 
Adjusted for baseline patient 
characteristics2 
4.47 (2.97 – 6.72)  1.67 (0.84 – 3.32) 2.70 (1.62 – 4.52) 1.69 (1.02 – 2.78) 2.42 (1.65 – 3.55) 
      
North America      
Crude 1.02 (0.62 – 1.67) 1.46 (0.91 – 2.34) 2.67 (1.88 – 3.81) 3.95 (3.07 – 5.08) 4.34 (3.47 – 5.42) 
Adjusted for baseline patient 
characteristics2 
0.88 (0.53 – 1.44) 1.25 (0.78 – 2.02) 2.30 (1.61 – 3.27) 3.40 (2.64 – 4.37) 3.72 (2.97 – 4.65) 
Additional adjustment for 0.69 (0.42 – 1.14) 0.99 (0.62 – 1.60) 1.80 (1.25 – 2.58) 2.65 (2.03 – 3.44) 2.86 (2.26 – 3.62) 
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transmission category, HIV-RNA 
and AIDS prior to ART initiation 
Additional adjustment for 
transmission category, HIV-RNA, 
AIDS prior to ART initiation and 
race/ethnicity in patients with 
available info on race/ethnicity 
0.53 (0.31 – 0.89) 0.92 (0.55 – 1.55) 1.48 (0.99 – 2.22) 2.39 (1.77 – 3.24) 2.78 (2.11 – 3.66) 
      
Central America and Caribbean      
Crude 11.27 (8.87 – 14.33) 4.61 (3.31 – 6.42) 3.28 (2.32 – 4.63) 2.73 (2.04 – 3.65) 2.88 (2.22 – 3.75) 
Adjusted for baseline patient 
characteristics2 
9.92 (7.79 – 12.63) 4.12 (2.95 – 5.74) 2.93 (2.07 – 4.15) 2.43 (1.82 – 3.26) 2.50 (1.92 – 3.26) 
 
1Mortality estimates corrected by using an inverse-probability-weighted estimator of the rate where weights are constant and equal to the inverse ratio of the 
patients who could be traced out of all patients who were lost to follow-up 
2 Baseline patient characteristics are age (<30, 30-44, 45-59, ≥60 years), CD4 T-cell count (0-24, 25-49, 50-99, 100-199, 200-349, ≥350 cells/mm3, unknown) 
and period of ART initiation (2000-2003, 2004-2007, 2008-2011, 2012-2014) 
3 Mortality estimates corrected by using a modification of the approach by Brinkhof and colleagues, which uses inflation factors to account for mortality under-
reporting, under the assumption that mortality under-ascertainment in West Africa was similar to that in East Africa. Death rates based on observed data were 
estimated for different durations on ART (0-3, 3-6, 6-12, 12-24, 24-48 months) and then multiplied by inflation factor for each specific duration on ART 
determined as the ratio of the lost-to-follow-up-adjusted death rates over the observed rates estimated within East African cohorts. 
 
 
 
 
 
 
Figure 1. Crude mortality rates per 100 person-years for women initiating ART by global region 
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Mortality rates per 100 p-y Duration on ART (months) 
0 – 3 3 - 6 6 - 12 12 - 24 24 - 48 
Europe 1.51 (1.25 – 1.82) 1.31 (1.07 – 1.60) 0.80 (0.66 – 0.96) 0.70 (0.61 – 0.82) 0.56 (0.49 – 0.64) 
East Africa      
   Non corrected 5.65 (5.34 – 5.98) 2.95 (2.71 – 3.20) 1.51 (1.38 – 1.65) 0.99 (0.91 – 1.08) 0.59 (0.54 – 0.64) 
   Corrected1 12.45 (11.30–13.73) 6.23 (5.38 – 7.20) 3.77 (3.28 – 4.32) 3.05 (2.72 – 3.43) 2.32 (2.07 – 2.59) 
West Africa      
   Non corrected 6.37 (5.76 – 7.04) 2.62 (2.23 – 3.08) 1.58 (1.35 – 1.83) 1.37 (1.22 – 1.55) 0.90 (0.80 – 1.01) 
   Corrected2 14.03 (13.12 – 15.02) 5.54 (4.96 – 6.19) 3.94 (3.58 – 4.33) 4.23 (3.95 – 4.53) 3.55 (3.34 – 3.76) 
South Africa 9.44 (8.80 – 10.11) 4.75 (4.29 – 5.26) 3.48 (3.18 – 3.80) 2.52 (2.32 – 2.73) 2.35 (2.18 – 2.52) 
South America 7.83 (5.44 – 11.27) 2.52 (1.31 – 4.85) 2.49 (1.55 – 4.01) 1.38 (0.86 – 2.22) 1.60 (1.12 – 2.29) 
North America 1.53 (0.97 – 2.43) 1.91 (1.24 – 2.92) 2.13 (1.58 – 2.87) 2.78 (2.28 – 3.41) 2.45 (2.05 – 2.93) 
Central America and Caribbean 17.02 (14.62-19.81) 6.03 (4.64 – 7.84) 2.61 (1.95 – 3.49) 1.92 (1.50 – 2.46) 1.63 (1.30 – 2.04) 
1Mortality estimates for East Africa corrected by using an inverse-probability-weighted estimator of the rate where weights are constant and equal to the inverse ratio of the 
patients who could be traced out of all patients who were lost to follow-up 
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2Death rates based on observed data were estimated for different durations on ART (0-3, 3-6, 6-12, 12-24, 24-48 months) and then multiplied by inflation factor for each specific 
duration on ART determined as the ratio of the lost-to-follow-up-adjusted death rates over the observed rates estimated within East African cohorts 
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Supplemental Table 1. List of countries represented in each region 
Europe 
Southern Europe: Croatia, Greece, Italy, Portugal, Serbia, Bosnia and Herzergovina, Slovenia, Spain 
Western Europe: Belgium, France, Germany, Luxembourg, Netherlands, Switzerland 
Northern Europe: Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden, United Kingdom 
Central and Eastern Europe: Bulgaria, Belarus, Czech Republic, Hungary, Poland, Romania, Russian Federation, Slovakia, 
Ukraine 
East Africa Kenya, Tanzania, Uganda, Zambia, Zimbabwe 
West Africa Benin, Burkina Faso, Cote d’Ivoire, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal, Togo 
South Africa Republic of South Africa 
South America Brazil, Chile, Peru 
North America Canada, United States 
Central America and 
the Caribbean Honduras, Haiti 
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Supplemental Table 2. Adjusted Mortality rate ratios (95% CI) compared to Europe by duration on antiretroviral therapy, under different 
restrictions: 
Mortality rate ratio Duration on ART (months) 
0 – 3 3 - 6 6 - 12 12 - 24 24 - 48 
East Africa 
Patients with documented or presumed 
heterosexual transmission 
7·61 (6·09 – 9·52) 4·59 (3·52 – 5·99) 4·82 (3·74 – 6·22) 5·06 (4·08 – 6·28) 4·03 (3·34 – 4·86) 
Patients starting ART post-2004 7·45 (5·84 – 9·50) 4·60 (3·44 – 6·15) 4·63 (3·51 – 6·09) 4·61 (3·66 – 5·80) 4·10 (3·32 – 5·06) 
Cohorts with >50% of data on CD4 cell 
counts at baseline 
7·70 (6·24 – 9·51) 4·54 (3·53 – 5·83) 4·52 (3·57 – 5·73) 4·09 (3·38 – 4·95) 3·64 (3·05 – 4·33) 
Cohorts with “very good” self-reported 
mortality ascertainment1 
NA NA NA NA NA 
      
West Africa      
Patients with documented or presumed 
heterosexual transmission 
9·43 (7·64 – 11·63) 4·40 (3·43 – 5·63) 5·00 (3·95 – 6·32) 6·99 (5·76 – 8·48) 6·20 (5·29 – 7·28) 
Patients starting ART post-2004 11·00 (8·83 – 13·88) 5·28 (4·01 – 6·94) 5·78 (4·48 – 7·47) 7·66 (6·21 – 9·46) 7·78 (6·45 – 9·38) 
Cohorts with >50% of data on CD4 cell 
counts at baseline 
NA NA NA NA NA 
Cohorts with “very good” self-reported 
mortality ascertainment1 
NA NA NA NA NA 
      
South Africa      
Patients with documented or presumed 
heterosexual transmission 
5·69 (4·59 – 7·05) 3·41 (2·66 – 4·36) 4·31 (3·42 – 5·45) 3·97 (3·25 – 4·85) 3·85 (3·26 – 4·56) 
Patients starting ART post-2004 5·38 (4·25 – 6·81) 3·42 (2·60 – 4·50) 4·03 (3·12 – 5·20) 3·62 (2·91 – 4·49) 3·97 (3·27 – 4·82) 
Cohorts with >50% of data on CD4 cell 
counts at baseline 
5·65 (4·62 – 6·92) 3·29 (2·62 – 4·15) 3·92 (3·17 – 4·86) 3·09 (2·59 – 3·67) 3·33 (2·85 – 3·89) 
Cohorts with “very good” self-reported 
mortality ascertainment1 
4·32 (3·01 – 6·21) 4·11 (2·48 – 6·79) 2·87 (2·00 – 4·12) 3·27 (2·34 – 4·57) 3·50 (2·64 – 4·64) 
      
South America      
Patients with documented or presumed 
heterosexual transmission 
4·76 (3·15 – 7·21) 1·84 (0·92 – 3·67) 2·95 (1·73 – 5·04) 2·23 (1·34 – 3·71) 2·74 (1·86 – 4·05) 
Patients starting ART post-2004 4·20 (2·64 – 6·69) 2·10 (1·04 – 4·23) 2·42 (1·31 – 4·48) 2·08 (1·21 – 3·58) 2·47 (1·57 – 3·90) 
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Cohorts with >50% of data on CD4 cell 
counts at baseline 
4·68 (3·12 – 7·00) 1·76 (0·89 – 3·47) 2·86 (1·72 – 4·77) 1·77 (1·08 – 2·90) 2·43 (1·67 – 3·54) 
Cohorts with “very good” self-reported 
mortality ascertainment1 
3·53 (2·13 – 5·86) 2·17 (0·96 – 4·91) 2·04 (1·13 – 3·69) 1·81 (1·02 – 3·21) 2·45 (1·56 – 3·85) 
      
North America      
Patients with documented or presumed 
heterosexual transmission 
0·71 (0·38 – 1·32) 0·90 (0·48 – 1·69) 2·15 (1·41 – 3·30) 3·47 (2·54 – 4·74) 3·55 (2·73 – 4·62) 
Patients starting ART post-2004 0·89 (0·48 – 1·63) 1·45 (0·83 – 2·56) 2·49 (1·60 – 3·86) 3·53 (2·52 – 4·95) 3·45 (2·50 – 4·74) 
Cohorts with >50% of data on CD4 cell 
counts at baseline 
0·86 (0·52 – 1·41) 1·22 (0·76 – 1·95) 2·20 (1·55 – 3·12) 3·19 (2·49 – 4·09) 3·45 (2·77 – 4·29) 
Cohorts with “very good” self-reported 
mortality ascertainment1 
0·68 (0·38 – 1·22) 1·60 (0·83 – 3·06) 1·71 (1·08 – 2·70) 3·58 (2·45 – 5·24) 3·72 (2·69 – 5·15) 
      
Central America and Caribbean      
Patients with documented or presumed 
heterosexual transmission 
10·51 (8·17 – 13·52) 4·49 (3·18 – 6·34) 3·38 (2·36 – 4·85) 3·20 (2·35 – 4·35) 2·81 (2·14 – 3·69) 
Patients starting ART post-2004 9·26 (7·00 – 12·27) 4·22 (2·88 – 6·20) 2·57 (1·69 – 3·91) 2·72 (1·93 – 3·82) 2·57 (1·87 – 3·53) 
Cohorts with >50% of data on CD4 cell 
counts at baseline 
9·54 (7·52 – 12·11) 4·15 (2·98 – 5·78) 2·99 (2·12 – 4·23) 2·52 (1·89 – 3·36) 2·38 (1·83 – 3·09) 
Cohorts with “very good” self-reported 
mortality ascertainment1 
NA NA NA NA NA 
 
All models are adjusted for the following baseline patient characteristics: age (<30, 30-44, 45-59, ≥60 years), CD4 T-cell count (0-24, 25-49, 50-99, 100-199, 
200-349, ≥350 cells/mm3, unknown) and period of ART initiation (2000-2003, 2004-2007, 2008-2011, 2012-2014) 
NA: Not applicable 
1 Analyses restricted to cohorts within each region reporting very good mortality ascertainment. Mortality rate ratios reported as NA means that no cohort 
within that region reported very good mortality ascertainment 
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